Anthracycline cardiotoxicity in long-term survivors of childhood cancer

@article{Scully2007AnthracyclineCI,
  title={Anthracycline cardiotoxicity in long-term survivors of childhood cancer},
  author={R. Scully and S. Lipshultz},
  journal={Cardiovascular Toxicology},
  year={2007},
  volume={7},
  pages={122-128}
}
Anthracycline chemotherapy is a widely-used and effective treatment for a wide spectrum of childhood cancers. Its use is limited by associated progressive and clinically significant cardiotoxic effects. Onset can be acute, early, or late. While acute onset is rare, long-term survivors have significantly elevated rates of cardiac morbidity and mortality. Major complications include cardiomyopathy, coronary artery disease, and atherosclerosis. Means of prevention and treatment continue to be… Expand
Epigenetic Changes Associated With Anthracycline‐Induced Cardiotoxicity
Childhood Malignancy and Cardiotoxicity of Anthracyclines
Cardiovascular effects of systemic cancer treatment.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 60 REFERENCES
Epidemiology of anthracycline cardiotoxicity in children and adults.
Cardiovascular trials in long-term survivors of childhood cancer.
  • S. Lipshultz, S. Colan
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.
  • K. Nysom, K. Holm, +8 authors S. Lipshultz
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.
Cardiac safety of liposomal anthracyclines.
Long-term effects of treatments for childhood cancers
Cardioprotective interventions for cancer patients receiving anthracyclines.
...
1
2
3
4
5
...